Compare DSP Healthcare Fund vs ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund
Risk | Very High | Very High |
Rating | 4.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.93 | 1.86 |
NAV | ₹38.50 | ₹38.47 |
Fund Started | 12 Nov 2018 | 25 Jun 2018 |
Fund Size | ₹3114.33 Cr | ₹6455.55 Cr |
Exit Load | Exit load of 0.50% if redeemed within 1 month. | Exit load of 1% if redeemed within 15 days. |
Risk
Very High
Very High
Rating
4.0
5.0
Min SIP Amount
₹100
₹100
Expense Ratio
1.93
1.86
NAV
₹38.50
₹38.47
Fund Started
12 Nov 2018
25 Jun 2018
Fund Size
₹3114.33 Cr
₹6455.55 Cr
Exit Load
Exit load of 0.50% if redeemed within 1 month.
Exit load of 1% if redeemed within 15 days.
1 Year | -4.95% | 0.60% |
3 Year | 20.42% | 26.13% |
5 Year | 14.48% | 16.47% |
1 Year
-4.95%
0.60%
3 Year
20.42%
26.13%
5 Year
14.48%
16.47%
Equity | 98.20% | 97.87% |
Cash | 1.80% | 2.13% |
Equity
98.20%
97.87%
Cash
1.80%
2.13%
Top 10 Holdings |
|
|
Top 10 Holdings
Cipla Ltd. | 8.69% |
Sun Pharmaceutical Industries Ltd. | 8.48% |
Ipca Laboratories Ltd. | 7.73% |
Globus Medical Inc | 6.78% |
Laurus Labs Ltd. | 6.52% |
Illumina Inc. (USA) | 6.07% |
Sai Life Sciences Ltd. | 5.23% |
Gland Pharma Ltd. | 5.09% |
Cohance Lifesciences Ltd. | 5.04% |
Apollo Hospitals Enterprise Ltd. | 4.40% |
Sun Pharmaceutical Industries Ltd. | 12.05% |
Cipla Ltd. | 7.90% |
Dr. Reddy's Laboratories Ltd. | 7.82% |
Divi's Laboratories Ltd. | 7.10% |
Mankind Pharma Ltd. | 6.44% |
Lupin Ltd. | 5.78% |
Aurobindo Pharma Ltd. | 5.19% |
Alkem Laboratories Ltd. | 3.66% |
Cohance Lifesciences Ltd. | 3.01% |
Syngene International Ltd. | 2.98% |
Name | - | - |
Start Date | - | - |
Name
-
-
Start Date
-
-
Description | The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 12 Nov 2018 | 25 Jun 2018 |
Description
The scheme seeks to generate consistent returns by predominantly investing in equity and equity related securities of pharmaceutical and healthcare companies.
The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies.
Launch Date
12 Nov 2018
25 Jun 2018